Highest-materiality recent filing
Edwards Q2 sales up 13.6% to $1.74B; raises full-year sales and TAVR guidance
Q2 sales $1.74B (+13.6% YoY); adjusted EPS $0.78; gross margin 77.5%.
Edwards Lifesciences appoints Theodora Mistras as CFO, effective May 29, 2026
Theodora Mistras appointed CFO effective May 29, 2026, succeeding Scott Ullem (announced October transition).
Edwards Q1 sales +16.7% to $1.65B; raises FY guidance on TAVR strength
Q1 sales $1.65B, +16.7% YoY; constant currency +12.7%; TAVR sales $1.20B, +14.4%.
Edwards Q4 sales $1.57B (+13.3%), TAVR +12%, TMTT >40% growth; FY2026 guidance raised
Q4 GAAP EPS $0.11, adjusted EPS $0.58; gross margin 78.1% (78.3% adjusted).
US District Court grants FTC motion for injunction blocking Edwards' acquisition of JenaValve; deal terminated.
Edwards Q3 sales rise 14.7% to $1.55B; raises FY EPS guidance to $2.56-$2.62
Q3 sales $1.55B (+14.7% YoY); adjusted EPS $0.67 vs $0.50 GAAP.
Edwards Lifesciences CFO Scott Ullem to step down by mid-2026; successor search underway
CFO Scott Ullem informed company on Oct. 30, 2025 of decision to transition by mid-2026.
FTC moved to block Edwards' proposed acquisition of JenaValve Technology; Edwards disagrees and will continue pursuing regulatory approval.
Edwards Q2 sales up 11.9% to $1.53B; raises full-year guidance
Q2 GAAP EPS $0.57; adjusted EPS $0.67.
Edwards Q1 sales $1.41B (+6.2%), TMTT surging 58%, guidance raised
Q1 sales $1.41B (+6.2% reported, +7.9% adjusted); GAAP EPS $0.62, adjusted EPS $0.64.
Edwards Q4 sales $1.39B (+9%), adjusted EPS $0.59; reiterates 2025 guidance
Q4 sales $1.39B (+9% YoY); TAVR $1.04B (+6%), TMTT $105M (+88%).
Edwards Q3 sales up 9% to $1.33B; TAVR +6%, TMTT +73%; adjusted EPS $0.67 beats guidance
Q3 sales from continuing ops $1.33B (+9% as-reported, +10% constant currency); adjusted EPS $0.67 ahead of July guidance.
Edwards completes $4.2B sale of Critical Care to BD, adds $1.5B buyback
Closed all-cash sale of Critical Care to BD (NYSE: BDX) for $4.2B.
Edwards Q2 revenue +8% CC, TAVR guidance cut to 5-7%; announces $1.2B in acquisitions
Q2 continuing ops sales $1.35B (+7% reported, +8% CC); adj. EPS $0.70, GAAP EPS $0.61.
Edwards Lifesciences exercises option to acquire Innovalve for ~$300M cash
Edwards Lifesciences (EW) acquires early-stage TMVR company Innovalve Bio Medical Ltd.
Edwards Lifesciences sells Critical Care unit to BD for $4.2B cash, ends spin-off
All-cash sale of Critical Care product group to BD (NYSE: BDX) valued at $4.2 billion.
Edwards Q1 sales $1.6B (+10%), TMTT +75%; raises FY sales guidance to high end 8-10%
Q1 sales $1.6B, up 10% reported and constant currency; GAAP EPS $0.58, adjusted EPS $0.66.
Edwards Q4 sales $1.53B (+14% YoY); 2024 guidance reiterated with higher TMTT outlook
Q4 2023 sales $1.53B (+14% reported, +13% constant currency); TAVR $979M (+13%).
Edwards plans tax-free spin-off of Critical Care, issues 2024 sales guidance $6.3-6.6B
Edwards plans tax-free spin-off of Critical Care at end of 2024; Katie Szyman to be CEO of new company.
Edwards Q3 sales $1.48B (+12%), EPS $0.63; TAVR grows 11%; guidance reaffirmed
Q3 revenue $1.48B (+12% reported, +11% constant currency); GAAP EPS $0.63, adjusted EPS $0.59.
Edwards Q2 sales $1.53B (+11% YoY); adj EPS $0.66; raises FY23 guidance
Q2 sales $1.53B (+11%/+12% constant currency); GAAP EPS $0.50 (incl. IP charge), adjusted EPS $0.66.
Edwards Q1 sales $1.46B (+9% YoY), adj EPS $0.62; raises FY guidance, CEO to retire
Q1 GAAP EPS $0.56; adjusted EPS $0.62 vs prior guidance implied range.
Edwards Q4 sales up 1% to $1.35B; adjusted EPS grows 25% to $0.64
Q4 TAVR sales flat at $868M; constant-currency growth 5%; U.S. procedures rose mid-single digits.
Edwards Lifesciences CEO Mike Mussallem retiring May 2023; Bernard Zovighian to become CEO
CEO Mussallem (70) to retire at May 11, 2023 annual meeting; will become non-executive chairman.
Edwards Lifesciences announces $750M accelerated share repurchase, initial ~8M shares
$750M ASR executed; initial delivery of ~8M shares, remainder based on VWAP over term.
GAAP EPS $0.55, adjusted EPS $0.61; $0.07/share charge from discontinuing HARPOON surgical mitral repair.
Edwards Q2 sales flat at $1.37B; lowers FY2022 outlook on FX, staffing
Q2 sales $1.37B flat YoY; underlying growth 5%. GAAP EPS $0.65, adjusted EPS $0.63.
Edwards Q1 sales $1.34B (+13% underlying), adjusted EPS $0.60; TAVR up 14% underlying
Q1 sales $1.34B, up 10% reported (13% underlying); adjusted EPS $0.60.
Edwards Q4 sales $1.33B (+12% YoY); adjusted EPS $0.51; guides FY22 sales $5.5-6.0B
Q4 sales $1.33B, up 12% (13% underlying); TAVR sales $872M (+12%); TMTT $25M.
Edwards Q2 sales $1.4B (+49% YoY); raises FY2021 sales & adjusted EPS guidance
Q2 2021 sales $1.4B, up 49% reported (44% underlying); diluted EPS $0.78, adjusted EPS $0.64.
On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position.
On July 10, 2024, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), appointed David T. Feinberg, M.D. to the Company’s Board of Directors (the “Board”), effective immediately.
Robert W.A. Sellers, Senior Vice President, Principal Accounting Officer of the Company, of his decision to retire, effective as of July 1, 2024
On the Retirement Date, Mr. Sellers will be succeeded by Andrew M. Dahl, currently Senior Vice President and Corporate Controller of the Company.
Michael A. Mussallem informed the Board of Directors (the Board) of his decision to retire as Non-Executive Chairman and a director of the Board which will be effective in conjunction with the Company’s annual meeting of stockholders on May 7, 2024
Martha H. Marsh has reached the retirement age set forth in the Company’s Corporate Governance Guidelines and will therefore not be nominated to stand for election to the Board at the 2024 Annual Meeting.
The Company expects to appoint Nicholas J. Valeriani, an independent director, to succeed Mr. Mussallem as Chairman of the Board.
the Board’s appointment of Larry Wood to an expanded role as corporate vice president and group president, Transcatheter Aortic Valve Replacement and Surgical Structural Heart effective January 1, 2023
At the 2023 Annual Meeting, Mr. Mussallem will be succeeded as CEO by Bernard J. Zovighian, currently corporate vice president and general manager for Edwards’ Transcatheter Mitral and Tricuspid Therapies (“TMTT”) business.
On December 6, 2022 the Board appointed Bernard J. Zovighian as President of the Company, effective January 1, 2023, until he becomes CEO on May 11, 2023.
On December 6, 2022, Michael A. Mussallem informed the Board of Directors (the “Board”) of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), of his decision to retire as Chief Executive Officer of Edwards in connection with Edwards’ Annual Meeting of Stockholders on May 11, 2023.
Max materiality 0.85 · Median 0.75 · Most common event earnings